# Plasma Therapy Market > Plasma Therapy Market Research Report By Application (Orthopedics, Dermatology, Dental, Cardiology), By Type (Platelet Rich Plasma, Platelet Rich Fibrin, Bone Marrow Aspirate), By End Use (Hospitals, Ambulatory Surgical Centers, Clinics), By Procedure Type (Invasive, Non-invasive) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.26% - **2024:** $ 4.83 Billion - **2025:** $ 5.28 Billion - **2035:** $ 12.79 Billion - **Key Players:** Grifols (ES), Takeda Pharmaceutical Company Limited (JP), CSL Behring (AU), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Hualan Biological Engineering Inc. (CN) **Report ID:** MRFR/HC/9249-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/plasma-therapy-market-10733 --- ## Market Summary ## **Plasma Therapy Market Overview** As per MRFR analysis, the Plasma Therapy Market Size was estimated at 4.42 (USD Billion) in 2023.The Plasma Therapy Market Industry is expected to grow from 4.83(USD Billion) in 2024 to 12.8 (USD Billion) by 2035. The Plasma Therapy Market CAGR (growth rate) is expected to be around 9.26% during the forecast period (2025 - 2035). ### **Key Plasma Therapy Market Trends Highlighted** The Plasma Therapy Market is witnessing several notable trends fueled by increasing awareness and advances in medical technologies. One of the key market drivers is the growing prevalence of chronic diseases, which has led to a rising demand for innovative therapies that utilize plasma-derived products. Moreover, the aging population worldwide is contributing to the greater need for regenerative treatments and therapies, targeting conditions that cause deterioration of bodily functions. This heightened focus on personalized medicine is pushing healthcare providers to explore more tailored approaches to treatment, thereby enhancing the adoption of plasma therapy.Opportunities within the Plasma Therapy Market continue to expand, particularly with increasing investments in research and development. Governments and health organizations are recognizing the potential of plasma therapy in wound healing, orthopedic issues, and aesthetic treatments, among others. Collaborations between research institutions and healthcare providers are paving the way for novel applications of plasma products. The ability to harness biological factors from an individual’s plasma presents a unique opportunity that can significantly improve patient outcomes and reduce overall healthcare costs. In recent times, trends show a noticeable increase in clinical trials aimed at exploring new therapeutic applications of plasma therapy, supported by regulatory bodies recognizing its potential.This aligns with a broader shift towards minimally invasive procedures. Additionally, there is growing interest in understanding the impact of platelet-rich plasma (PRP) on sports medicine, where athletes seek faster recovery times. The acceptance of aesthetic procedures like PRP facelifts also reflects a growing consumer inclination toward non-surgical solutions, further accentuating the market momentum. Overall, these trends suggest a vibrant and evolving landscape for the Plasma Therapy Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Plasma Therapy Market Drivers** ### **Rising Incidence of Chronic Diseases** The rising frequency of chronic illnesses, including cancer and autoimmune disorders, is driving the Plasma Therapy Market Industry. According to the World Health Organization, the worldwide cancer incidence is expected to climb by nearly 47% between 2020 and 2040, resulting in an increase of approximately 27 million cases each year. This spike needs sophisticated treatment alternatives, such as plasma therapy, resulting in increased demand. Established organizations, such as the American Society of Clinical Oncology, are actively exploring cancer treatment options that include plasma therapy. The rise in chronic illness cases needs creative solutions, which accelerate market expansion and increase the attraction of plasma treatment. ### **Advancements in Medical Technology** Technological advancements in medical devices and treatment methodologies are contributing significantly to the expansion of the Plasma Therapy Market Industry. Enhanced technologies in plasma extraction and processing have improved treatment efficacy and patient safety. The European Commission's Horizon 2020 program has funded numerous Research and Development initiatives aimed at propelling technological innovations in regenerative medicine, including plasma therapies. These advancements not only enhance treatment outcomes but also broaden application scopes, thereby driving market growth. ### **Increasing Focus on Regenerative Medicine** There is a growing emphasis on regenerative medicine globally, significantly nurturing the Plasma Therapy Market Industry. According to the National Institutes of Health, investments in regenerative medicine initiatives reached a staggering 7 billion USD in the past five years. This focus includes utilizing plasma therapy to treat various conditions effectively. Organizations such as the Regenerative Medicine Foundation advocate for the advancement of plasma-based treatments, which are becoming increasingly recognized as critical components of modern therapeutic strategies. This trend indicates a robust future for plasma therapy within the regenerative medicine sector. ### **Growing Awareness and Acceptance of Plasma Treatments** The increasing awareness and acceptance of plasma treatments among healthcare professionals and patients have become crucial in driving the Plasma Therapy Market Industry. Various health awareness programs conducted by non-profit organizations and academic institutions have successfully highlighted the benefits and efficacy of plasma therapies. A report by the International Plasma Association indicates that awareness campaigns have led to a 35% increase in the number of patients opting for plasma-based therapies over the last three years. As awareness grows, more patients and healthcare providers are likely to choose plasma therapy, bolstering market growth. ## **Plasma Therapy Market Segment Insights** ### **Plasma Therapy Market Application Insights  ** The Plasma Therapy Market is witnessing significant growth across its Application segment, with a particular focus on key areas such as Orthopedics, Dermatology, Dental, and Cardiology. In 2024, the market is projected to reach a valuation of approximately 4.83 USD Billion, reflecting robust demand driven by the rising adoption of regenerative therapies. The Orthopedics segment holds a considerable market share, valued at 1.25 USD Billion in 2024 and expected to rise to 3.35 USD Billion by 2035, indicating its vital role in enhancing patient recovery and healing through the use of plasma-based treatments. Similarly, the Dermatology application emphasizes the importance of plasma therapy in skin-related conditions, with a valuation of about 1.15 USD Billion in 2024, expected to grow to 3.2 USD Billion by 2035, showcasing the rising prevalence of dermatological ailments and the demand for effective treatment solutions. The Dental segment is valued at 1.05 USD Billion in 2024, with projections reaching up to 2.8 USD Billion in 2035, reflecting the increasing integration of plasma therapies in dental surgeries and procedures, further highlighting its significance in dental care advancement. The Cardiology application, on the other hand, represents a significant area, valued at 1.38 USD Billion in 2024, growing to a projected 3.45 USD Billion by 2035, underlining the importance of plasma therapies in cardiovascular health and intervention. The entire segment is expected to benefit from innovations in technology, growing healthcare expenditures, and increased awareness regarding the therapeutic advantages of plasma therapy, driving a noteworthy compound annual growth rate. However, market challenges such as regulatory hurdles and the high cost associated with plasma therapy may impact widespread adoption. Nevertheless, the opportunities presented by advancements in plasma technology and the rising demand for minimally invasive procedures create a favorable environment for growth within the Plasma Therapy Market, contributing to an enhanced focus on applications that meet the diverse needs of patients globally. ** Source: Primary Research, Secondary Research, MRFR Database and Analyst Review** ### **Plasma Therapy Market Type Insights  ** The Plasma Therapy Market is projected to reach a valuation of 4.83 USD Billion in 2024, establishing a significant momentum in the industry. This market showcases diverse types, notably including Platelet Rich Plasma, Platelet Rich Fibrin, and Bone Marrow Aspirate. Platelet Rich Plasma is gaining traction as a regenerative treatment, particularly in orthopedics and dermatology, where its ability to promote healing enhances its demand. Similarly, Platelet Rich Fibrin is becoming increasingly relevant due to its natural properties that support tissue regeneration, making it a preferred choice in dental surgeries and wound healing. Bone Marrow Aspirate holds a prominent role in clinical applications for various disorders, being a vital source of stem cells that support patient recovery. The escalating focus on minimally invasive procedures and rising awareness regarding the benefits of plasma therapies are driving the market growth. Additionally, advancements in technology are paving the way for innovative treatment options, ensuring a robust future for the Plasma Therapy Market. As these types continue to evolve, they are expected to cater to a growing patient base seeking effective regenerative therapies on a global scale. ### **Plasma Therapy Market End Use Insights  ** The Plasma Therapy Market is witnessing substantial growth, driven significantly by its End Use across various facilities. By 2024, the market is reflected at a valuation of 4.83 USD Billion, indicating a robust interest in plasma therapies across medical settings. Hospitals are essential players in this segment, as they cater to a diverse range of patients requiring advanced treatments and therapies. Ambulatory Surgical Centers also play a crucial role by providing outpatient services that enhance patient access to plasma therapies, thus facilitating their adoption in non-emergency situations. Clinics contribute by offering localized treatment options, making plasma therapy more accessible, particularly for chronic conditions. The market is witnessing trends such as increased collaborations and technological advancements that further streamline the treatment processes within these facilities. Growth drivers include an increasing prevalence of chronic diseases and rising awareness regarding the efficacy of plasma treatments. However, the market faces challenges like regulatory hurdles and the need for extensive Research and Development to establish standardized treatment protocols. Overall, the Plasma Therapy Market segmentation highlights strong demand across Hospitals, Ambulatory Surgical Centers, and Clinics, reflecting their crucial roles in enhancing patient care and expanding treatment options globally. ### **Plasma Therapy Market Procedure Type Insights  ** The Plasma Therapy Market, particularly in the context of Procedure Type, shows a diverse landscape with its classification into Invasive and Non-invasive procedures. By 2024, the Plasma Therapy Market is valued at 4.83 USD Billion, reflecting the increasing adoption of these therapy types in clinical settings. The growth in this market is propelled by the rising prevalence of chronic diseases and the need for effective treatment options, leading to a significant demand for both invasive and non-invasive procedures. Invasive procedures tend to dominate this segment due to their capability to deliver targeted and potent treatment outcomes, catering to various medical conditions, which gives them a competitive edge.However, Non-invasive procedures are gaining traction owing to their minimal risk and shorter recovery times, hence appealing to a broader patient demographic. Market growth is also supported by technological advancements and innovations that enhance the efficacy and safety profiles of these therapies. Overall, the Plasma Therapy Market data highlights the critical role of Procedure Type in shaping industry trends, driven by patient preference and clinical effectiveness, which subsequently results in a healthy market evolution from 2025 to 2035. ### **Plasma Therapy Market Regional Insights  ** The Regional segment of the Plasma Therapy Market shows notable variations in valuation and growth prospects. In 2024, the North America segment is valued at 2.0 USD Billion, dominating the market with a significant share due to advanced healthcare infrastructure and increased investments in Research and Development. Europe follows with a valuation of 1.5 USD Billion, driven by a growing prevalence of chronic diseases and innovative therapeutic options that utilize plasma. South America, with a valuation of 0.3 USD Billion, exhibits the potential for growth, albeit at a slower pace, influenced by limited healthcare access and varying regulation dynamics.The Asia Pacific region stands at 0.8 USD Billion in 2024, recognized for its rapidly evolving healthcare sector, which creates ample opportunities for market expansion. Lastly, the Middle East and Africa, at 0.23 USD Billion, represent the least valued yet promising sector, facing challenges like infrastructure, but also benefiting from rising healthcare investments. The increasing demand for personalized medicine and the expansion of therapeutic applications in these regions are contributing to the overall market growth in the Plasma Therapy Market statistics over the years. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Plasma Therapy Market Key Players and Competitive Insights** The Plasma Therapy Market has experienced significant growth driven by advancements in medical technology and an increasing demand for innovative therapeutic solutions. Competitive insights within this market reveal a dynamic landscape where companies are striving to leverage their expertise in plasma-based treatments for various medical applications. As more healthcare providers and patients recognize the potential benefits of plasma therapy, key players are focused on expanding their capabilities, enhancing product offerings, and improving patient outcomes. The landscape is characterized by strategic partnerships, research and development initiatives, and a push towards regulatory approvals that cater to evolving market needs.Hematogenix plays a vital role within the Plasma Therapy Market by capitalizing on its robust portfolio of plasma-derived products and services. The company has established a substantial presence globally, recognized for its commitment to quality and innovation in the field of regenerative medicine. Hematogenix's strengths lie in its state-of-the-art laboratory facilities and a team of experienced medical professionals dedicated to advancing plasma therapy techniques. The company emphasizes research and clinical trials to validate the efficacy of its offerings, positioning itself as a leader in the market. By focusing on personalized treatment options, Hematogenix has created a reputation for excellence, ensuring its competitive advantage in an expanding healthcare environment.LFB Group is another significant player in the Plasma Therapy Market, known for its comprehensive range of plasma-derived therapies and innovative solutions. The company has a strong international presence, providing critical products that address various medical conditions, including immunodeficiencies and bleeding disorders. LFB Group's strengths include its cutting-edge research capabilities, a commitment to quality assurance, and strategic mergers and acquisitions that have expanded its market reach and product offerings. With a focus on collaboration with healthcare professionals and institutions worldwide, LFB Group has successfully positioned itself at the forefront of the industry, continuously evolving its portfolio to meet patient needs. The company's diverse array of key products and services reflects a dedication to enhancing patient care through advanced therapies, consolidating its significant role in the global market landscape. ### **Key Companies in the Plasma Therapy Market Include** - Hematogenix - LFB Group - Orthocell - Octapharma - Grifols - Fresenius Kabi - Advatech - Sangamo Therapeutics - Baxter International - CSL Behring - BioLife Plasma Services - Progenitor Cell Therapy - Takeda Pharmaceutical Company - Vericel Corporation - Kedrion Biopharma ## Plasma Therapy Industry Developments - **Q2 2024: Grifols to Acquire Plasma Collection Centers from Kedrion for $450 Million** Grifols announced the acquisition of 25 plasma collection centers in the United States from Kedrion for $450 million, expanding its plasma supply network and strengthening its position in the plasma-derived therapies market. - **Q2 2024: CSL Behring Opens New Plasma Fractionation Facility in Germany** CSL Behring inaugurated a new state-of-the-art plasma fractionation facility in Marburg, Germany, aimed at increasing production capacity for immunoglobulins and other plasma-derived therapies. - **Q3 2024: Takeda Receives FDA Approval for New Plasma-Derived Immunoglobulin Therapy** Takeda secured FDA approval for its latest plasma-derived immunoglobulin therapy, designed to treat patients with primary immunodeficiency, marking a significant regulatory milestone for the company. - **Q3 2024: Octapharma Launches New Plasma Donation Center in Texas** Octapharma announced the opening of a new plasma donation center in Houston, Texas, as part of its ongoing expansion strategy to meet growing demand for plasma-derived medicines. - **Q4 2024: BioLife Solutions Signs Multi-Year Plasma Supply Agreement with Emergent BioSolutions** BioLife Solutions entered into a multi-year agreement to supply plasma to Emergent BioSolutions, supporting the production of plasma-based therapies for rare diseases. - **Q4 2024: Grifols Appoints New Chief Executive Officer** Grifols announced the appointment of a new CEO, effective immediately, to lead the company’s global plasma therapy operations and strategic growth initiatives. - **Q1 2025: CSL Limited Completes $1.2 Billion Acquisition of Vifor Pharma’s Plasma Business** CSL Limited finalized its $1.2 billion acquisition of Vifor Pharma’s plasma business, expanding its portfolio of plasma-derived products and global market reach. - **Q1 2025: Kedrion and LFB Announce Strategic Partnership for Plasma Collection in Europe** Kedrion and LFB Group formed a strategic partnership to jointly develop and operate plasma collection centers across Europe, aiming to secure a stable plasma supply for therapeutic manufacturing. - **Q2 2025: Takeda Opens New Plasma Processing Plant in Japan** Takeda inaugurated a new plasma processing facility in Osaka, Japan, to increase production capacity for plasma-derived therapies and support regional healthcare needs. - **Q2 2025: Octapharma Receives EMA Approval for Expanded Use of Plasma-Derived Product** Octapharma received European Medicines Agency (EMA) approval for expanded indications of its plasma-derived product, allowing its use in additional patient populations. - **Q3 2025: Grifols Launches Next-Generation Plasma Fractionation Technology** Grifols introduced a next-generation plasma fractionation technology at its main facility, aiming to improve efficiency and yield in the production of plasma-derived medicines. - **Q3 2025: CSL Behring Wins Major Contract to Supply Plasma Therapies to NHS England** CSL Behring secured a multi-year contract to supply plasma-derived therapies to NHS England, strengthening its presence in the UK healthcare market. ## **Plasma Therapy Market Segmentation Insights** - ### **Plasma Therapy Market Application Outlook** - Orthopedics - Dermatology - Dental - Cardiology - ### **Plasma Therapy Market Type Outlook** - Platelet Rich Plasma - Platelet Rich Fibrin - Bone Marrow Aspirate - ### **Plasma Therapy Market End Use Outlook** - Hospitals - Ambulatory Surgical Centers - Clinics - ### **Plasma Therapy Market Procedure Type Outlook** - Invasive - Non-invasive - ### **Plasma Therapy Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Supportive Regulatory Frameworks The presence of supportive regulatory frameworks is an essential driver for the Plasma Therapy Market. Regulatory bodies are increasingly recognizing the therapeutic potential of plasma-derived products, leading to streamlined approval processes for new therapies. This regulatory support not only fosters innovation but also instills confidence among investors and manufacturers. As a result, the Plasma Therapy Market is likely to benefit from an influx of new products and therapies entering the market. Furthermore, favorable regulations may encourage research and development initiatives, ultimately expanding the range of available plasma therapies. This supportive environment could significantly enhance market growth prospects in the coming years. ### Rising Incidence of Chronic Diseases The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and autoimmune conditions appears to be a primary driver for the Plasma Therapy Market. As these diseases often require advanced treatment options, plasma therapy emerges as a viable solution. According to recent data, chronic diseases account for a substantial portion of healthcare expenditures, prompting healthcare providers to seek innovative therapies. The demand for effective treatment modalities is likely to escalate, thereby enhancing the growth prospects of the Plasma Therapy Market. Furthermore, the aging population, which is more susceptible to these conditions, may further contribute to the rising demand for plasma-based therapies, indicating a robust market trajectory. ### Technological Innovations in Plasma Processing Technological advancements in plasma processing techniques are likely to play a crucial role in shaping the Plasma Therapy Market. Innovations such as improved separation methods and enhanced storage solutions for plasma products are emerging, which could lead to more efficient and effective therapies. The introduction of automated systems for plasma collection and processing may also streamline operations, reducing costs and increasing accessibility. Market data suggests that these technological improvements could enhance the overall quality of plasma therapies, making them more appealing to both healthcare providers and patients. As technology continues to evolve, the Plasma Therapy Market may witness significant growth driven by these advancements. ### Increasing Investment in Research and Development Investment in research and development (R&D) within the Plasma Therapy Market appears to be on the rise, driven by the need for innovative treatment solutions. Pharmaceutical companies and research institutions are allocating substantial resources to explore the therapeutic applications of plasma. This focus on R&D is likely to yield new therapies and improve existing ones, thereby expanding the market. Data indicates that increased funding for plasma research could lead to breakthroughs in treatment efficacy and safety, which may attract more patients to plasma therapies. As the industry evolves, the emphasis on R&D is expected to be a key factor in driving the growth of the Plasma Therapy Market. ### Growing Awareness and Acceptance of Plasma Therapy There seems to be a notable increase in awareness and acceptance of plasma therapy among both healthcare professionals and patients. Educational initiatives and successful case studies have contributed to a more informed public, which may lead to higher adoption rates of plasma therapies. The Plasma Therapy Market is witnessing a shift in perception, as patients increasingly recognize the potential benefits of these treatments. This growing acceptance is likely to be reflected in market data, showing an upward trend in the utilization of plasma therapies across various medical fields. As more practitioners advocate for plasma therapy, the market could experience accelerated growth, driven by patient demand and clinical endorsements. ## Future Outlook Future projections for The Plasma Therapy Market size reflect increasing adoption of regenerative medicine. It is projected to grow at a 9.26% CAGR from 2024 to 2035, driven by technological advancements, increasing applications, and rising demand for regenerative medicine. **New opportunities:** - Development of personalized plasma therapy solutions for chronic conditions. Expansion of telehealth platforms for remote plasma therapy consultations. Investment in automated plasma collection and processing technologies. By 2035, the Plasma Therapy Market is expected to be robust, reflecting substantial growth and innovation. ## Segment Insights ### By Application: Orthopedics (Largest) vs. Dermatology (Fastest-Growing) The Plasma Therapy Market segments into various applications, prominently featuring Orthopedics, Dermatology, Dental, and Cardiology. Among these, Orthopedics holds the largest market share, primarily driven by the increasing prevalence of orthopedic injuries and the growing preference for minimally invasive treatments. Dermatology, while relatively smaller, is experiencing rapid growth due to rising awareness of skin conditions and the pursuit of aesthetic enhancements through plasma therapy. Increased clinical applications in Orthopedics and Dermatology are expected to expand the Plasma Therapy Market Size. Orthopedics (Dominant) vs. Dermatology (Emerging) Orthopedics remains the dominant segment in the plasma therapy market due to its extensive application in treating sports injuries, arthritis, and post-surgical recovery. This segment benefits from advanced clinical research validating the effectiveness of plasma therapies for healing musculoskeletal injuries. In contrast, Dermatology, as an emerging segment, reflects a growing focus on non-surgical aesthetic procedures and innovative treatments for skin rejuvenation. With increasing patient demand for aesthetic solutions and a shift towards [regenerative medicine](https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220), the Dermatology segment is likely to expand significantly in the coming years. ### By Type: Platelet Rich Plasma (Largest) vs. Platelet Rich Fibrin (Fastest-Growing) In the Plasma Therapy Market, the 'By Type' segment showcases significant diversity, with Platelet Rich Plasma (PRP) commanding the largest market share. PRP has established itself as a cornerstone therapy due to its extensive research backing and clinical applications in various medical fields, particularly in orthopedics and aesthetics. Following PRP, Platelet Rich Fibrin (PRF) is rapidly gaining traction, especially among practitioners looking for alternatives that provide natural healing without additional reagents. Meanwhile, Bone Marrow Aspirate (BMA) holds a smaller share yet remains a critical component in regenerative medicine due to its rich stem cell content. Growth trends indicate an increasing preference for minimally invasive procedures, which favor the development of PRF as the fastest-growing segment. This shift is partly driven by patient demand for natural healing methodologies and advances in medical technologies that enhance the efficacy of plasma therapies. Furthermore, the aging population and rising sports-related injuries are contributing to higher adoption rates across all sub-segments, cementing the importance of these therapies in modern medical practice. Platelet Rich Plasma (Dominant) vs. Bone Marrow Aspirate (Emerging) Platelet Rich Plasma (PRP) stands as the dominant force in the Plasma Therapy Market due to its well-established efficacy and wide-ranging applications. PRP is derived from the patient’s own blood, making it a highly biocompatible treatment option, particularly favored in cosmetic procedures and orthopedic therapies. On the other hand, Bone Marrow Aspirate (BMA) is emerging as a viable alternative, primarily because of its rich stem cell content that supports regenerative processes. While PRP is often the go-to choice for immediate results, BMA is gaining recognition for its long-term benefits in promoting healing and tissue regeneration. As practitioners continue to explore innovations in treatment, both segments will likely coexist, catering to diverse patient needs and preferences. ### By End Use: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) The Plasma Therapy Market analysis shows a distinct distribution among key end-use segments, with hospitals commanding the largest share. These institutions cater to a broad patient demographic, providing comprehensive treatment options that utilize advanced plasma therapies. Ambulatory surgical centers, although smaller in market share, are rapidly gaining traction due to their cost-effective treatment options and convenience for patients. Clinics also play a vital role, though they represent a smaller fraction compared to hospitals and ambulatory surgical centers. The global plasma therapy market is benefiting from a shift toward personalized and precision medicine. Growth trends in the Plasma Therapy Market are driven by increasing awareness and acceptance of plasma-based treatments in various medical conditions. The rush towards minimally invasive treatments in ambulatory surgical centers showcases a shift in patient preference, while hospitals continue to invest in advanced technologies and skilled personnel to enhance patient outcomes. Clinics are adapting by incorporating plasma therapy into their offering, but must contend with the leading presence of larger institutions. Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals are the dominant force in the Plasma Therapy Market given their extensive infrastructure and capability to offer a wide variety of plasma treatments. They typically integrate these therapies into larger treatment protocols, attracting a diverse patient base. In contrast, ambulatory surgical centers are emerging as a compelling alternative, capitalizing on patient demands for quicker, less expensive procedures that do not require prolonged hospital stays. These centers focus on outpatient services, providing personalized plasma treatments that appeal to tech-savvy patients seeking convenience. The flexibility and specialized services of ambulatory surgical centers are proving attractive, making them a critical player in the ongoing evolution of plasma therapy market dynamics. ### By Procedure Type: Invasive (Largest) vs. Non-invasive (Fastest-Growing) In the Plasma Therapy Market, the Invasive procedure type represents the largest segment, capturing a significant portion of the overall market share due to its established efficacy in treating various conditions. This technique is widely recognized for delivering direct and immediate results, particularly in cases involving severe ailments. In contrast, the Non-invasive segment emerges as the fastest-growing, gaining traction among patients seeking minimal discomfort and quicker recovery times. This transition reflects a shift in patient preference towards less invasive options that promote safety and convenience. Growth trends indicate a greater emphasis on developing non-invasive alternatives to plasma therapy, driven by technological advancements and increased awareness of treatment options. This surge is further supported by a rising demand for procedures that minimize risks and optimize healing times. Research and development are focusing on enhancing the effectiveness of non-invasive methods, leading to a projected increase in their adoption among healthcare professionals and patients alike. Procedure Type: Invasive (Dominant) vs. Non-invasive (Emerging) The Invasive procedure type is considered dominant within the Plasma Therapy Market, typically characterized by its ability to deliver concentrated therapeutic effects directly to the affected area. This segment is favored for its effectiveness in managing chronic conditions and provides healthcare providers with a reliable treatment option. Conversely, the Non-invasive procedure type is rapidly emerging, appealing to a growing segment of patients concerned about the risks associated with traditional methods. Non-invasive techniques leverage advanced technologies to ensure efficacy while significantly reducing recovery time and discomfort. The emergence of this segment signifies a crucial shift in patient preferences, with a focus on innovative approaches that align with the modern healthcare narrative of prioritizing patient safety and comfort. ## Regional Market Share Analysis The Regional segment of the Plasma Therapy Market shows notable variations in valuation and growth prospects. In 2024, the North America segment is valued at 2.0 USD Billion, dominating the market with a significant share due to advanced healthcare infrastructure and increased investments in Research and Development. Europe follows with a valuation of 1.5 USD Billion, driven by a growing prevalence of chronic diseases and innovative therapeutic options that utilize plasma. South America, with a valuation of 0.3 USD Billion, exhibits the potential for growth, albeit at a slower pace, influenced by limited healthcare access and varying regulation dynamics. The Asia Pacific plasma therapy market is witnessing a surge in medical tourism for advanced regenerative treatments. This region stands at 0.8 USD Billion in 2024, recognized for its rapidly evolving healthcare sector, which creates ample opportunities for market expansion. Local manufacturing of cost-effective centrifuge kits is a primary growth driver for the Asia Pacific Plasma Therapy Market Size. Lastly, the Middle East and Africa, at 0.23 USD Billion, represent the least valued yet promising sector, facing challenges like infrastructure, but also benefiting from rising healthcare investments. The increasing demand for personalized medicine and the expansion of therapeutic applications in these regions are contributing to the overall market growth in the Plasma Therapy Market statistics over the years. ## Competitive Benchmarking The Plasma Therapy Market has experienced significant growth driven by advancements in medical technology and an increasing demand for innovative therapeutic solutions. Competitive insights within this market reveal a dynamic landscape where companies are striving to leverage their expertise in plasma-based treatments for various medical applications. As more healthcare providers and patients recognize the potential benefits of plasma therapy, key players are focused on expanding their capabilities, enhancing product offerings, and improving patient outcomes. The landscape is characterized by strategic partnerships, research and development initiatives, and a push towards regulatory approvals that cater to evolving market needs.Hematogenix plays a vital role within the Plasma Therapy Market by capitalizing on its robust portfolio of plasma-derived products and services. The company has established a substantial presence globally, recognized for its commitment to quality and innovation in the field of regenerative medicine. Hematogenix's strengths lie in its state-of-the-art laboratory facilities and a team of experienced medical professionals dedicated to advancing plasma therapy techniques. The company emphasizes research and clinical trials to validate the efficacy of its offerings, positioning itself as a leader in the market. By focusing on personalized treatment options, Hematogenix has created a reputation for excellence, ensuring its competitive advantage in an expanding healthcare environment.LFB Group is another significant player in the Plasma Therapy Market, known for its comprehensive range of plasma-derived therapies and innovative solutions. The company has a strong international presence, providing critical products that address various medical conditions, including immunodeficiencies and bleeding disorders. LFB Group's strengths include its cutting-edge research capabilities, a commitment to quality assurance, and strategic mergers and acquisitions that have expanded its market reach and product offerings. With a focus on collaboration with healthcare professionals and institutions worldwide, LFB Group has successfully positioned itself at the forefront of the industry, continuously evolving its portfolio to meet patient needs. The company's diverse array of key products and services reflects a dedication to enhancing patient care through advanced therapies, consolidating its significant role in the global market landscape. ## Recent News & Developments - **Q2 2024: Grifols to Acquire Plasma Collection Centers from Kedrion for $450 Million** Grifols announced the acquisition of 25 plasma collection centers in the United States from Kedrion for $450 million, expanding its plasma supply network and strengthening its position in the plasma-derived therapies market. - **Q2 2024: CSL Behring Opens New Plasma Fractionation Facility in Germany** CSL Behring inaugurated a new state-of-the-art plasma fractionation facility in Marburg, Germany, aimed at increasing production capacity for immunoglobulins and other plasma-derived therapies. - **Q3 2024: Takeda Receives FDA Approval for New Plasma-Derived Immunoglobulin Therapy** Takeda secured FDA approval for its latest plasma-derived immunoglobulin therapy, designed to treat patients with primary immunodeficiency, marking a significant regulatory milestone for the company. - **Q3 2024: Octapharma Launches New Plasma Donation Center in Texas** Octapharma announced the opening of a new plasma donation center in Houston, Texas, as part of its ongoing expansion strategy to meet growing demand for plasma-derived medicines. - **Q4 2024: BioLife Solutions Signs Multi-Year Plasma Supply Agreement with Emergent BioSolutions** BioLife Solutions entered into a multi-year agreement to supply plasma to Emergent BioSolutions, supporting the production of plasma-based therapies for rare diseases. - **Q4 2024: Grifols Appoints New Chief Executive Officer** Grifols announced the appointment of a new CEO, effective immediately, to lead the company’s global plasma therapy operations and strategic growth initiatives. - **Q1 2025: CSL Limited Completes $1.2 Billion Acquisition of Vifor Pharma’s Plasma Business** CSL Limited finalized its $1.2 billion acquisition of Vifor Pharma’s plasma business, expanding its portfolio of plasma-derived products and global market reach. - **Q1 2025: Kedrion and LFB Announce Strategic Partnership for Plasma Collection in Europe** Kedrion and LFB Group formed a strategic partnership to jointly develop and operate plasma collection centers across Europe, aiming to secure a stable plasma supply for therapeutic manufacturing. - **Q2 2025: Takeda Opens New Plasma Processing Plant in Japan** Takeda inaugurated a new plasma processing facility in Osaka, Japan, to increase production capacity for plasma-derived therapies and support regional healthcare needs. - **Q2 2025: Octapharma Receives EMA Approval for Expanded Use of Plasma-Derived Product** Octapharma received European Medicines Agency (EMA) approval for expanded indications of its plasma-derived product, allowing its use in additional patient populations. - **Q3 2025: Grifols Launches Next-Generation Plasma Fractionation Technology** Grifols introduced a next-generation plasma fractionation technology at its main facility, aiming to improve efficiency and yield in the production of plasma-derived medicines. - **Q3 2025: CSL Behring Wins Major Contract to Supply Plasma Therapies to NHS England** CSL Behring secured a multi-year contract to supply plasma-derived therapies to NHS England, strengthening its presence in the UK healthcare market. ## Report Scope | MARKET SIZE 2024 | 4.83(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 5.277(USD Billion) | | MARKET SIZE 2035 | 12.79(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.26% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Grifols (ES), Takeda Pharmaceutical Company Limited (JP), CSL Behring (AU), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Hualan Biological Engineering Inc. (CN) | | Segments Covered | Application, Type, End Use, Procedure Type, Regional | | Key Market Opportunities | Advancements in regenerative medicine drive growth in the Plasma Therapy Market. | | Key Market Dynamics | Rising demand for innovative treatments drives competition and regulatory scrutiny in the Plasma Therapy Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Plasma Therapy Market by 2035?** A: The Plasma Therapy Market is projected to reach a valuation of 12.79 USD Billion by 2035. **Q: What was the market valuation of the Plasma Therapy Market in 2024?** A: In 2024, the Plasma Therapy Market was valued at 4.83 USD Billion. **Q: What is the expected CAGR for the Plasma Therapy Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Plasma Therapy Market during the forecast period 2025 - 2035 is 9.26%. **Q: Which application segment is expected to show significant growth in the Plasma Therapy Market?** A: The Orthopedics application segment is expected to grow from 1.45 USD Billion in 2024 to 3.85 USD Billion by 2035. **Q: What are the key players in the Plasma Therapy Market?** A: Key players in the Plasma Therapy Market include Grifols, Takeda Pharmaceutical Company Limited, CSL Behring, and Octapharma. **Q: How does the market for Platelet Rich Plasma compare to other types in 2025?** A: The market for Platelet Rich Plasma is anticipated to grow from 1.45 USD Billion in 2024 to 3.85 USD Billion by 2035, indicating strong demand. **Q: What is the expected growth for the Ambulatory Surgical Centers segment in the Plasma Therapy Market?** A: The Ambulatory Surgical Centers segment is projected to increase from 1.5 USD Billion in 2024 to 4.0 USD Billion by 2035. **Q: What is the market size for Non-invasive procedures in the Plasma Therapy Market?** A: The market for Non-invasive procedures is expected to grow from 3.38 USD Billion in 2024 to 8.92 USD Billion by 2035. **Q: Which type of plasma therapy is anticipated to have the highest growth rate?** A: Bone Marrow Aspirate is expected to grow from 2.18 USD Billion in 2024 to 5.74 USD Billion by 2035, indicating a robust growth trajectory. **Q: What is the projected market size for Clinics in the Plasma Therapy Market by 2035?** A: The Clinics segment is projected to grow from 1.33 USD Billion in 2024 to 3.39 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/plasma-therapy-market-10733*